![]() |
市场调查报告书
商品编码
1761522
全球家禽药品市场:依动物类型、产品类型、疾病类型、给药途径和地区划分的机会与预测(2018-2032)Global Poultry Pharmaceuticals Market Assessment, By Animal Type, By Product Type, By Disease Type, By Route of Administration, By Region, Opportunities and Forecast, 2018-2032F |
全球家禽药品市场预计将从2024年的65.6亿美元成长至2032年的105.9亿美元,在2025-2032年的预测期内,年复合成长率为6.17%。
家禽药品市场是支持动物健康的关键领域,在开发和供应家禽用药、保健品、疫苗等方面发挥重要作用。该市场在保护家禽健康、预防疾病以及生产安全的肉类和蛋类产品方面发挥关键作用。该市场服务于小规模生产者和商业家禽养殖户,并解决各种健康问题,例如细菌性和病毒性疾病、寄生虫疾病以及营养障碍。
市场提供抗生素、抗病毒药物、疫苗、益生菌和饲料添加剂等必需产品,以促进免疫力和生长。目前,人们对抗生素抗药性的日益担忧,促使人们关注植物性植物疗法和疫苗以及精准医疗。此外,各国的监管架构都设定了产品安全性和有效性的标准,并采取生物安全措施来遏止疾病爆发。推动该行业成长的两个关键因素是:对禽肉和禽蛋的需求不断成长、家禽养殖方法的改进,以及对人畜共患病的认识不断加深。由于家禽产量的扩大,新兴国家的市场迅速扩张;而已开发国家则因注重先进的治疗方案和可持续的农业实践而实现了成长。未来,生物技术和诊断技术的进步预计将促进更精准、更有效的治疗方法的开发,进一步发展家禽医药市场。该行业将继续蓬勃发展,重点关注疾病控制、生产力最大化和道德畜牧业。
本报告研究了全球家禽药品市场,并提供了市场定义和概述、市场规模趋势和预测、各个细分市场的详细分析、监管环境、临床试验趋势、案例研究、影响市场成长的因素分析、竞争格局以及主要公司的概况。
Global poultry pharmaceuticals market is projected to witness a CAGR of 6.17% during the forecast period 2025-2032, growing from USD 6.56 billion in 2024 to USD 10.59 billion in 2032. The poultry pharmaceutical market functions as an essential component of animal health, which creates and distributes medications, together with health products and vaccines for poultry. The market plays a vital role in protecting poultry health while protecting against diseases and producing safe food products. The market serves commercial poultry operations together with smaller producers because it treats various health conditions, which include bacterial and viral diseases, as well as parasitic diseases and nutritional deficiencies.
The market delivers essential products, which include antibiotics together with antivirals and vaccines and probiotics, and feed additives that promote immunity and growth. The industry now focuses on phytogenic solutions together with vaccines and precision health management because of growing antimicrobial resistance concerns. The regulatory frameworks establish product safety standards, and the efficacy standards and biosecurity protocols work to stop disease outbreaks. The industry expands because of two main factors: rising poultry needs and improved farming approaches, and enhanced knowledge of zoonotic diseases. Developing nations experience rapid market expansion because of growing poultry production, while developed nations direct their focus toward advanced therapeutic solutions and sustainable agricultural practices. The future development of poultry pharmaceuticals will follow biotechnology and diagnostic improvements to create specific and effective treatment options. The industry remains dynamic by prioritizing disease control, maximum productivity, and ethical farming practices.
Additionally, to support the market expansion of the poultry pharmaceuticals market, companies are collaborating to enhance production and quality. For instance, in March 2025, RODEC Pharma Ltd signed an exclusive marketing and distribution agreement with UniFAHS to bring next-generation bacteriophage-based solutions to India's poultry, dairy, and pet health sectors. The increasing threat of antimicrobial resistance (AMR) creates a need for bacteriophage solutions because these treatments naturally fight bacterial infections in livestock without harming animals. The product range targets gut health enhancement, together with immunity building and improved animal performance to enable poultry and livestock farmers to minimize antibiotic use while boosting productivity.
Rising Poultry Consumption Drives Global Poultry Pharmaceuticals Market Growth
The global poultry pharmaceutical market experiences quick growth as consumers choose poultry for their protein meal needs. The expanding global population, together with improved economic conditions in developing regions, makes poultry meat and eggs fundamental food sources which result in expanded poultry farming operations. The rising production requirements generated an increased need for vaccines, together with antibiotics and nutritional supplements, which protect poultry health and optimize flock productivity. Poultry health management depends on pharmaceuticals as a key element because they stop food safety problems and shield birds from avian influenza and other disease outbreaks. The private sector, alongside government departments, makes important investments in modern veterinary medicine and vaccination programs, which stimulate market growth. Food safety standards and consumer preference for antibiotic-free poultry products drive the poultry industry toward developing natural healthcare solutions. The poultry industry's rapid growth will drive continuous pharmaceutical industry expansion, which will create sustainable health products for poultry farming.
For instance, in March 2025, Alembic Pharmaceuticals Ltd. entered into a strategic business partnership with Amlan International, which functions as the animal health division of Oil-Dri Corporation of America, to introduce advanced poultry health solutions and this partnership enables broader distribution of sophisticated feed additives, which improve gut health and enhance nutrient uptake and FCR, and deliver enhanced poultry production outcomes to satisfy increasing protein consumption requirements.
Increase in Causes of Poultry Disease Boosts Global Poultry Pharmaceutical Market Demand
The poultry industries face increasing disease outbreaks, which drive higher demand for pharmaceutical products used in their treatment. Farmers implement preventive and therapeutic solutions because disease outbreaks cause major losses through high bird death rates and lowered egg production, and trade limitations. The market for vaccines, together with antibiotics and antiviral drugs, and disinfectants, has increased because these products help protect poultry flocks from infections. The poultry market expansion is supported by government-backed vaccination programs along with biosecurity protocols implemented by poultry producers. Pharmaceutical companies are expanding production capacities and innovating new treatments to meet rising needs. The increasing consumer knowledge about food safety, combined with disease prevention, has resulted in greater use of modern veterinary medical products. The poultry pharmaceutical business will experience major growth because Asia-Pacific and Africa maintain large poultry operations while battling ongoing disease challenges. Pharmaceutical products demonstrate rising demand because these items protect poultry health, which helps maintain worldwide food supply stability.
For instance, in March 2025, Boehringer Ingelheim International GmbH launched its next-generation three-in-one single-dose innovative solution that defends against Bursal, alongside Newcastle and Marek's diseases.
Chicken Animal Type Holds Largest Global Poultry Pharmaceutical Market Share
The poultry pharmaceutical market maintains its biggest segment through chicken products since large-scale farming operations combine with disease prevention needs. Poultry farming operations around the world raise chickens for their meat and eggs, thus exposing them to numerous diseases. The requirement for vaccines, together with antibiotics and health products, emerges from the need to sustain production levels. Large-scale poultry farms require rigorous vaccination and medication protocols to combat avian influenza and Newcastle disease, and coccidiosis, which are common poultry diseases. The pharmaceutical demand rises because broiler chickens grow quickly, while layer chickens need an extended production time. Various countries enforce vaccination rules to protect food safety, which strengthens the market leadership position. The worldwide demand for chicken protein drives ongoing investments in pharmaceutical solutions that boost production efficiency. The pharmaceutical supply chain for chickens is more extensive and standardized than for turkeys and ducks, thus making chickens the main target for veterinary drug manufacturers. The ongoing increase in poultry consumption will sustain this pattern.
For instance, in March 2025, Merck Animal Health, which operates as MSD Animal Health outside of the United States and Canada, announced the approval of NOBILIS MULTRIVA REOm for chicken protection from the European Commission The vaccine functions by actively immunizing chickens so their offspring receive passive immunity which decreases disease symptoms and viraemia caused by avian reovirus (ARV) genotypes 1 and 4. The vaccine also protects against ARV genotypes 2, 3 and 5.
North America Dominates the Global Poultry Pharmaceuticals Market Share
The North America poultry pharmaceutical market shows clear leadership in the global market because of multiple market-driving factors. The region maintains an advanced industrial poultry market through its large-scale commercial operations, which need effective disease prevention and treatment methods. The high per capita poultry meat and egg consumption in North America leads producers to focus on maintaining flock health and productivity, which drives demand for innovative pharmaceutical solutions. The implementation of strict rules combined with active support for animal welfare and food safety stands as a fundamental requirement. Healthcare providers utilize vaccines together with probiotics and nutraceuticals as alternative health solutions because regulatory frameworks promote responsible antibiotic use. The pharmaceutical industry dedicates substantial funds to research and development, while precision farming technologies and advanced diagnostics experience quick adoption to support the ongoing creation of effective poultry health products.
For instance, in August 2024, Elanco Animal Health Incorporated announced a 2500-square-foot expansion of its biological manufacturing facility in Elwood, Kansas and invest USD 130 million, set to be completed by 2026, will support the growth of its monoclonal antibody (mAb) platform, building on the robust expertise already present at this facility.
Impact of U.S. Tariffs on the Global Poultry Pharmaceuticals Market
The implementation of U.S. poultry pharmaceutical tariffs creates a market disturbance that raises production costs for farmers who need imported vaccines, antibiotics, and supplements to protect their flocks. The increased tariffs create supply chain blockages, which raise prices and generate potential shortages that threaten poultry health and lower production output. The poultry business must decide between absorbing price increases into profit margins or charging consumers more, resulting in decreased market sales of poultry products. Producers will pursue cheaper alternatives that could result in inferior products, which threaten both food safety standards and animal welfare conditions. The combined market pressures will lower poultry production volumes, which will decrease meat and egg supply, thus affecting food security. The poultry industry will suffer major damage from these tariffs if effective countermeasures are not implemented.
Key Players Landscape and Outlook
Continuous innovation, together with strategic market adaptation practices, characterizes the landscape of poultry pharmaceuticals. The sector's companies dedicate extensive funds to research and development for creating better poultry health solutions. The development of new vaccines targets both new and recurring diseases while researchers explore probiotic and phytogenic options to reduce antibiotic use due to antimicrobial resistance concerns. These companies choose geographic expansion as their primary strategy to increase their market presence by targeting the rising poultry industries in developing countries. The collaboration between these companies with academic institutions and other biotech firms and local distributors helps them enhance their abilities to develop products while improving their distribution networks. The companies use technological approaches, which include in-ovo vaccination and advanced diagnostics, along with precision farming methods, to create improved disease management tools for worldwide poultry production of healthier and more productive birds.
For instance, in November 2024, Ceva Animal Health (Ceva) launched its innovative Ceva Genesys for automatic and accurate broiler male and female separation at hatch to achieve better flock homogeneity.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.